Introduction
Mucopolysaccharidosis type I (MPS I) is a recessive genetic disease and is one of more than 40 known lysosomal storage diseases. It is caused by a deficiency of the lysosomal enzyme a-L-iduronidase (IDUA), which is needed for catabolism of the glycosaminoglycans dermatan sulfate and heparan sulfate. 1 This deficiency results in a progressive, lysosomal storage disease that includes central nervous system (CNS) as well as systemic involvement. Children homozygous for null mutations of the IDUA gene begin to exhibit a severe phenotype, Hurler syndrome, in their early years, and symptoms tend to become progressively more severe as storage material accumulates. Typical characteristics of the disease include abnormal features, organ malfunctions, mental retardation and early death.
Potential treatments for MPS I include bone marrow or cord blood transplantation, [2] [3] [4] enzyme replacement 5, 6 and gene therapy. [7] [8] [9] [10] A combination of treatments is also possible. 11, 12 Each type of treatment has its relative merits and limitations, but all three types rely on the ability of cells to take up IDUA via the mannose-6-phosphate receptor. 13 Secretion and subsequent uptake of enzyme is often referred to as cross-correction.
For enzyme replacement therapy, purified enzyme is infused into the circulatory system and is widely distributed to a variety of tissues and cell types. This has been shown to be effective in dog 14, 15 and cat 16 models of MPS I, and in humans with the disease. 5, 6 Systemic administration of enzyme therapy for MPS I has recently been approved by the FDA and may be the therapy of choice for many cases. 5, 6, 17 Problems with this approach to therapy are that massive amounts of purified enzyme are required, treatment must be repeated indefinitely, immunological intolerance may develop and therapy to the brain is limited by the blood-brain barrier (BBB). Using the MPS I dog model, it has been demonstrated that immune tolerance to IDUA replacement therapy can be induced using cyclosporine A and azathioprine. 18 Also using the dog model, it has recently been shown that IDUA administered into the cerebrospinal fluid via intrathecal (i.t.) injection resulted in widespread distribution of the enzyme in brain. 19 Although treatment was short term, it was accompanied by a substantial reduction in storage vacuoles. Thus, the i.t. route of delivering enzyme appears to successfully circumvent the BBB and may prove to be useful in conjunction with systemic delivery.
Using allogeneic bone marrow transplant, normal hematopoietic stem cells are established in the patient and these provide a continuing source of secreted enzyme that can be taken up by the mutant cells of various tissues. 20 Success of this approach appears to be variable with all the dangers and limitations inherent in bone marrow transplant. 2, 3 A variation of this approach is transplant of stem cells from umbilical cord blood. 4 Transplant treatments in general are limited by the low frequency of compatible donors, the high mortality and morbidity of the procedure and the potential for graftversus-host disease. The BBB also remains a formidable problem. In principle, these problems can be reduced by genetically altering stem cells to overproduce the missing enzyme and reimplanting them in the patient. This type of approach has shown promise in mouse models of MPS III B 21 and MPS VII 22 where storage material in brain was reduced after transplantation.
In vivo gene therapy for IDUA has not been reported for humans, but holds promise based on animal models for MPS I 7-10 and other lysosomal storage diseases, particularly MPS VII (see Cheng and Smith 23 for review). Cells transduced with a functional gene sequence provide centers of IDUA production, which then supply enzyme to non-transduced cells. Again, the BBB limits access of circulating IDUA to brain cells. It also limits transduction of brain cells by excluding gene therapy vectors that are administered intravenously (i.v.).
To extend gene therapy to the CNS, it is necessary either to cross the BBB or to circumvent it. Vectors carrying a complete gene sequence are necessarily composed of large molecules, and the brain is well adapted to excluding them. Thus, engineering a mechanism that safely subverts this barrier is a challenge. However, injecting vector directly into the brain has been shown in many cases to result in localized transduction. 23 Problems with this approach include the invasiveness of the procedure, the small volume of vector that can be delivered and the possible need for multiple sites of injection, 24, 25 especially in larger animals. 26 Nevertheless, Desmaris et al. 8 have shown that a single, intrastriatal injection of IDUA viral vector can provide enzyme and storage reduction throughout most of the brain. An alternative to intracranial injection that has shown promise in MPS VII mice is i.t. administration of vector into the cerebrospinal fluid; a single administration can cause widespread, long-lasting expression of the missing enzyme within the brain, resulting in extensive reduction of storage material. 27, 28 A variety of viral vectors have been employed to deliver genes to animal models of lysosomal storage disease. Results have been variable, but perhaps most impressive in dog and mouse models of MPS VII using retroviral 29 and adeno-associated virus (AAV) 28, 30, 31 vectors. Using an AAV vector administered i.v. to newborn MPS I mice, Hartung et al. 7 demonstrated IDUA activity persisting for at least 5 months. Tissues having measurable activity, including parts of the brain, had reduction in storage vacuoles, and treated mice were improved in several characteristics typical of MPS I mutants. Experiments using a lentiviral vector administered i.v. to MPS I mice also provided extensive relief from MPS I characteristics when administered to newborns and partial improvement when administered to young adults. 9, 10 Only animals treated as newborns had significant IDUA in the brain. To specifically treat the brain in MPS I mice, Desmaris et al. 8 used AAV vectors of serotypes 2 and 5. They concluded that the AAV-5 vector was more effective owing to wider distribution in the brain after a single intracranial injection. Using a cat model of a-mannosidosis to more closely approximate treatment of a human-sized brain, Vite et al. 26 showed that intracranial injection of an AAV-1 vector at multiple sites provided widespread correction of neuropathology. Thus, several vectors employing different modes of administration have demonstrated therapeutic potential for treating lysosomal storage diseases in the brain.
Here, to further improve gene therapy to the brain, we have treated MPS I mice by i.t. administration of an AAV-IDUA vector. Adult rather than newborn mice were treated. Although treatment of newborns might be expected to be more effective, treatment of adult mice may be more relevant to future treatment in humans. During development beyond the neonatal stage, the BBB in mice becomes more restrictive. Therefore, adult mice provide a model more comparable to human children. 32 Data presented indicate that the i.t. route of administration effectively delivers vector to the brain resulting in the expression of IDUA and the reduction of storage.
Results

Vectors
Two rAAV vectors were prepared and tested: one with the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) to increase the translational utility of the transcript and one without. The two vectors were packaged in AAV-2 capsid and compared. AAVIDUAw (with the WPRE) yielded 1.5 times as much IDUA activity per particle 24 h after transduction of 293 cells. For both vectors, the amount of IDUA activity generated was linear with particle number (data not shown). To compare expression in vivo, the vectors were injected into MPS I mice via the i.t. route and IDUA activity in the brain was measured at least 6 weeks later. On average, the AAV-IDUAw vector yielded 3.2 times as much activity as AAV-IDUA (six animals for each vector and two vector doses were used). Although the WPRE provided a relatively small increase in expression, the increase was consistent and AAV-IDUAw was chosen for subsequent experiments. Vector expression in the brain was shown to persist for at least 48 weeks.
Tissue distribution of a-L-iduronidase in treated mice
Adult MPS I mice were treated by i.v. or i.t. injection of AAV-IDUAw at a dose of 4 Â 10 10 particles. Six weeks later, mice were killed and tissues were collected for enzyme assay. Brains were subdivided into three coronal sections to provide a gross approximation of enzyme distribution within this organ. Intravenous administration resulted in substantial activity in liver (66% of normal) and lesser amounts in heart, spleen, kidney and lung. There was very little activity in brain (0.6% of normal). This suggested that neither transduction by the vector nor uptake of circulating enzyme was significant in brain. In contrast, animals treated by i.t. administra-CNS therapy for MPS I G Watson et al tion of the vector expressed IDUA almost exclusively in the brain (liver, heart, spleen, kidney and lung were o0.6% normal). Although one i.t. treated animal (#1058) had only limited activity in the brain, the other five had substantial activity ranging up to 730% of normal activity (Table 1) . Animal-to-animal variation was considerable and probably reflects the difficulty of doing the i.t. injections exactly the same in each animal. Distribution of IDUA among the three sections of the brain was not uniform; the hindbrain section (mostly cerebellum) tended to be highest and the mid-section lowest.
To better define the distribution of IDUA in treated mice, sagittal brain sections were immunostained and observed microscopically. Animals treated with 2 Â 10 9 particles administered i.t. were observed 6 weeks to 3 months later. Imaging entire 100 mm sagittal sections of brain by confocal microscopy indicated a broad distribution of IDUA-positive cells with higher concentrations in olfactory bulb and cerebellum ( Figure 1a ). This was consistent with the gross distributions shown in Table 1 . In general, neurons appeared to be the major cell type transduced by AAV-IDUAw ( Under the staining conditions and specific antibody used, normal levels of IDUA in non-mutant mice were near the threshold of detection. This suggested that positive cells were transduced and that they substantially overproduced IDUA, but that the uptake of IDUA by adjacent non-transformed cells was below the background level of detection. It should be noted that even a small fraction of normal IDUA activity, well below the detection limit of the immunostaining, should be sufficient to eliminate storage material.
Dose response
A total of 25 mice were administered different concentrations of the vector by the i.t. route and analyzed 6 weeks later by enzyme assay of brain homogenates. In spite of the high animal-to-animal variation, there was a statistically significant correlation between vector dose and enzyme activity in forebrain (P ¼ 0.004) and midbrain (P ¼ 0.01) sections (Figure 2a and b) . In hindbrain sections, where enzyme activity and the extent of variation were highest, the correlation was not statistically significant for the number of mice tested ( Figure 2c ).
Reduction of storage vacuoles
To observe the effects of gene therapy on lysosomal storage vacuoles, brain sections from treated and control mice were fixed, stained and observed by electron or light microscopy. Figure 3 shows electron microscopy of brain sections from MPS I mice treated i.t. with either a control vector (AAV-GFP) or AAV-IDUAw. In cortical regions, the most frequent and prominent storage was in perivascular cells ( Figure 3c ). Microglial cells in cerebral cortex also showed evidence of substantial storage, and particularly striking was the often close association of these cells with neurons ( Figure 3a ). This 'capping' of neurons with storage cells was characteristic of untreated MPS I mice. Six weeks after treatment with AAV-IDUAw (7 Â 10 9 particles), similar examples of neuronal capping and extensive storage were not found, and most cells appeared normal (Figure 3b and d) . Obvious storage in cortical neurons was rarely observed in untreated MPS I mice and was not observed in treated mice. In contrast, neurons (specifically Purkinje cells) in cerebellum were major sites of storage in untreated animals (see below).
To quantify the effects of gene therapy on storage, light microscopy of 0.5-mm-thick sections of plastic-embedded tissue was used. This allowed the examination of larger fields with more cells than was feasible with electron microscopy. Figure 4 shows cerebellum and cerebral cortex (adjacent to hippocampus) from treated and untreated MPS I mice. Inspection suggested that treated Figure 4D and E). The number of cortical microglia and perivascular cells with storage was also reduced ( Figure 4A and B), although a number of cortical perivascular cells with storage seemed to persist in some treated mice. Importantly, the extent of storage in these persistent cells was dramatically reduced even if it was not totally eliminated.
To better estimate the frequency of cells with storage vacuoles in treated and control mice, multiple fields of brain sections were scored and tabulated. To be conservative, all cells having any apparent vacuoles that might be attributable to lysosomal storage were scored as positive. This resulted in low positive scores for normal control mice and much higher scores for untreated MPS I mice (Table 2) . Treatment with either 2 Â 10 9 or 4 Â 10 10 particles of AAV-IDUAw decreased the frequency of Purkinje cells with storage to levels not significantly different from normal. The same was true for the numbers of microglia with storage observed in cerebral cortex. The frequency of perivascular cells with storage was reduced significantly in two of the three treated mice scored. The third, with a P-value of 0.03, did not quite meet the criterion (Pp0.025) for statistical significance. However, in two of the treated animals, the reduced frequency of perivascular cells with storage was still significantly more than normal. In these cases, the partial reduction in frequency of perivascular cells with storage was also accompanied by a reduction in the amount of storage material per cell. Thus, the net effect of gene therapy was at the very least a substantial reduction in overall storage in the brain. Virtually complete elimination of detectable storage vacuoles appears to be possible at the higher dose of AAV-IDUAw.
Discussion
To deliver an IDUA gene to the brain in MPS I mice, we chose an AAV-2 vector. Vectors based on AAV-2 were known to transduce neurons, to have the potential for long-term expression after a single dose and to be amenable to administration via an i.t. route. 27, 33 In addition, however, other viral vectors are also likely to be successful in transducing brain cells following i.t. administration. Other serotypes of AAV can provide vectors that are recognized by different cell surface receptors and by a potentially larger population of cells. 34, 35 The results of Desmaris et al. 8 indicate that an AAV-5 rather than an AAV-2 vector results in a broader distribution of IDUA in the brain. Also, other serotypes may express more rapidly and efficiently. 36 Alternatively, lentiviral vectors have been shown to be capable of delivering and expressing an IDUA gene to brain. 10 Preliminary results (G Watson, unpublished) suggest that a lentiviral vector carrying the IDUA gene also can be successfully introduced into the CNS via the i.t. route. Thus, the use of different vectors administered i.t. is likely to alter and in some cases improve the number, efficiency and distribution of cell transduction events in the brain.
Transduced cells that overproduce IDUA should secrete relatively high amounts of IDUA and thus provide more enzyme via cross-correction to nontransduced cells. To achieve overproduction, we used a cytomegalovirus (CMV) promoter/enhancer that, in previous experiments with the b-glucuronidase gene, proved to have long-term, high activity. 27, 28, 37 In our hands, this CMV promoter provided higher, sustained expression than EF1-a and ubiquitin promoters (G Watson, unpublished). To further enhance IDUA expression, we tested vectors with and without the WPRE, which appears to stabilize mRNA transcripts, thus Log (IDUA) Figure 2 Correlation between vector dose and enzyme response. AAV-IDUAw at different doses was administered intrathecally, and animals were killed 6 weeks later. a-L-iduronidase (IDUA)-specific activities in (a) forebrain, (b) mid-brain and (c) hindbrain sections were measured and expressed as the percentage of activity in normal control mice. Although logarithm plots are shown for illustration, statistical analysis was on linear data. Using simple linear regression, the correlation between dose and response was significant for forebrain (P ¼ 0.004) and mid-brain (P ¼ 0.010) but not for hindbrain (P ¼ 0.710).
CNS therapy for MPS I G Watson et al
allowing more protein translation per transcript. 38 AAVIDUAw, the vector with the WPRE, was about three times more efficient in IDUA expression in the brain.
A comparison of i.v. and i.t. administration of AAVIDUAw at high doses (4 Â 10 10 particles) to mature MPS I mice indicated that neither vector itself nor its IDUA product crossed the BBB in significant amounts. In i.v. treated animals, IDUA was minimal in the brain, although some other tissues (particularly the liver) had substantial activity. Conversely, in i.t. treated animals, IDUA was confined primarily to the CNS. The distinction between treating adult or newborn mice is significant. It is known that at the time of birth the BBB in mice is less restrictive than in adults. 32 Thus, it has been shown that systemic administration of either enzyme replacement therapy 39 or gene therapy 27, 30 to newborn MPS VII mice has a beneficial effect on lysosomal storage in the brain. For MPS I, Hartung et al. 7 showed that i.v. administration of an AAV vector to newborn mice also resulted in sufficient brain IDUA to reduce, but not completely eliminate, evidence of lysosomal storage. Similarly, Kobayashi et al. 10 observed therapy in the brain after systemic administration of a lentiviral vector to newborn MPS I mice. Systemic treatment of adult MPS I mice was not effective in the brain. 9, 10 Because humans are more developed at the time of birth than are mice, the BBB is expected to be more restrictive in neonatal humans. Furthermore, MPS I is often not diagnosed until age 1 or 
2 or even older, so the adult mouse is probably a better model for treatment of human MPS I. 8 Recently, Sferra et al. 31 have shown that systemic treatment via intrahepatic administration of AAV vector to adult MPS VII mice can actually reduce storage in the brain provided that the dose of vector is high enough (e.g., 3 Â 10 12 particles). Here, however, we show that i.t. administration is a much more efficient and effective means of delivering therapy to the CNS. Relatively low doses of AAV-IDUAw were still able to generate enzyme activity in the brain and reduce storage. At an i.t. dose of 2 Â 10 9 particles, storage in Purkinje cells in the cerebellum was essentially eliminated. In cerebral cortex, however, some perivascular cells with storage persisted, although the amount of storage material per cell was dramatically reduced. At an i.t. dose of 4 Â 10 10 particles, even storage in perivascular cells could be eliminated, although there was considerable variability from one treated mouse to another. With incomplete effects on storage after treating newborn MPS I mice, Hartung et al. 7 still showed improved results in open field tests, indicating that biochemical and histopathological improvements were correlated with neurological/behavioral improvement. It is not clear just how much storage material can be tolerated in MPS I patients, but it is clear that there is a broad range in the severity of the phenotype and that even very small amounts of IDUA activity are beneficial. Thus, even with relatively low doses of vector, we might expect to see substantial physiological improvement and at higher doses possibly complete normalization.
To effect a marked improvement in overall health determined by neurological, physiological and developmental parameters, both i.t. and i.v. administration of gene therapy might be employed to provide both CNS and systemic treatment. 28 Alternatively, gene therapy to the CNS might be combined with systemic enzyme replacement therapy. It remains to be seen if i.t. administration of an AAV vector is equally effective in larger mammals where greater diffusion distances may limit effective distribution of the vector and/or its therapeutic product. However, encouraging results using MPS I dogs showed that i.t. administration of IDUA does indeed provide a remarkably wide distribution of the enzyme with attendant reduction in storage. 19 This implies that IDUA secreted from transduced brain cells into the cerebrospinal fluid might be effectively redistributed even in mammals much larger than a mouse.
In summary, i.t. administration provided a relatively non-traumatic and effective means of delivering AAVIDUAw to the CNS. The resulting IDUA activity was widely, but not uniformly, distributed within the brain and was confined primarily to the CNS. At high doses of vector, normal and even higher levels of IDUA activity in brain could be achieved and storage could be virtually eliminated. At a lower dose, there was still sufficient IDUA activity to substantially reduce levels of lysosomal storage, particularly in Purkinje neurons. As it appears to be effective for both MPS I and MPS VII, the i.t. route of vector administration could also be promising for other lysosomal storage diseases with neural involvement.
Materials and methods
Animals
An MPS I mouse colony was established from heterozygous breeders generously provided by E Neufeld. The IDUA gene in these mice had been disrupted by insertion of a neomycin resistance gene in exon 6 and 
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G Watson et al the resulting knockout mutation was repeatedly backcrossed into the C57BL/6 (B6) strain. 40 Homozygous mutant mice were generated by mating heterozygous females with either heterozygous or homozygous mutant males. Progeny were genotyped by both IDUA enzyme assay and PCR using primers that flanked the neomycin gene insert. Tail tips provided biopsy material for these determinations. Confirmed MPS I mice (homozygous for the knockout mutation) were generally 2-4 months old at the time of treatment.
For i.v. treatment, mice were injected via the tail vein. For i.t. treatment, mice were first anesthetized with Avertin (tribromoethanol). Then a small incision (less than 1 cm) was made through the skin over the spine. Through this incision, the positions of individual vertebrae were discernable. A 30-gauge needle was inserted between two vertebrae in the lower thoracic region and into the i.t. space. A volume of 50-100 ml was injected slowly over a 5 min period either by hand or by pump. After removal of the needle, the incision was sutured and mice were allowed to recover on a heating pad before being returned to a mouse holding room. At specified times after treatment, mice were killed and tissues were collected. Pieces of tissue were either placed in fixative for histology or frozen in liquid nitrogen and stored at À701C for later assay of enzyme activity. All protocols employing animals were first approved by an Institutional Animal Care and Use Committee.
Adeno-associated virus vectors
Vector plasmids pAB1S and pAB1W were derived from pV4.1cmGUS 28, 37 by excising the mGUS sequence and substituting the sequence for human IDUA cDNA 41 using a BamH1 restriction site at the 5 0 end and XhoI at the 3 0 end. This provided an IDUA coding sequence driven by the CMV promoter/enhancer and terminated by a human growth hormone polyadenylation signal. To make pAB1W from pAB1S, 600 bp (an HpaI fragment) of LacZ stuffer sequence was deleted from the region between the polyadenylation signal and the downstream inverted terminal repeat. A WPRE sequence (approximately 600 bp) was then inserted in the 3 0 untranslated region of the IDUA cDNA between the restriction sites XhoI (5 0 ) and BglII (3 0 ). Adeno-associated virus vectors were packaged from pAB1S and pAB1W using a triple transfection protocol, 42 purified by heparin column chromatography 43 and titered by DNase digestion/dot blot 44 as described before. 28 Single large preparations of AAV-IDUA and AAV-IDUAw were used for the experiments reported and had titers of 2 Â 10 11 and 4 Â 10 11 particles/ml, respectively. Vectors were diluted in sterile, isotonic saline for injection.
a-L-Iduronidase activity
Frozen tissue samples were weighed and homogenized in buffer (10 mM NaPO 4 , pH 5.8, 0.1 mM dithiothreitol, 0.1% Triton X-100). a-L-Iduronidase activity was determined by a fluorometric procedure using 4-methylumbelliferyl-a-L-iduronide (4MU-I, supplied by BioMarin Pharmaceutical Inc., Novato, CA, USA) as substrate. Assay mixtures contained homogenate, 0.5 mM 4MU-I, 0.1% Triton X-100 and 0.2 M Na formate, pH 3.5, in a final volume of 0.1 ml. Reactions were incubated for 1 or 2 h at 371C and stopped by the addition of 1 ml stop buffer (0.2 M Na 2 CO 3 , 0.32 M glycine, pH 10.5). Fluorescence of the 4MU product was determined using an Amicon fluorometer with excitation and emission wavelengths of 365 and 455 nm, respectively. One unit of enzyme activity is defined as 1 mmol of 4MU product per hour. Specific activity was calculated as units per gram tissue (wet weight) and results are reported as relative specific activity, that is, percentage of normal, wild-type activity for each tissue.
Histology
For bright field microscopy, tissues were fixed in 2.3% glutaraldehyde in 0.05 M sodium cacodylate, pH 7.4, postfixed in 1% aqueous osmium tetroxide, embedded in Araldite epoxy resin, cut into 0.5-mm-thick sections and stained with toluidine blue. For electron microscopy ultrathin sections were cut from the same blocks and stained with uranylacetate and lead citrate.
For confocal laser microscopy, mice were deeply anesthetized with sodium pentobarbital (200 mg/kg i.p.; Abbott Laboratories, North Chicago, IL, USA) and transcardially perfused for 1 min with 0.9% sodium chloride (10 ml) and then for 10 min with 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS), pH 
Indirect immunofluorescence
To examine the distribution of IDUA, we stained freefloating vibratome brain sections with a rabbit polyclonal antibody to recombinant human IDUA (BP13BL2, BioMarin Pharmaceutical Inc.) at a dilution of 1:3000. Sections were preincubated with 5% non-fat milk in PBS with 0.3% Triton X-100. They were then incubated overnight at 41C with primary antibody. The sections were then rinsed in PBS (20 min, three changes) and incubated for 1 h at room temperature with a biotinylated donkey anti-rabbit secondary antibody (1:200; Jackson ImmunoResearch Labs, West Grove, PA, USA). After rinsing with PBS (20 min, three changes), sections were incubated with fluorescein isothiocyanate (FITC)-conjugated streptavidin (1:500; Jackson ImmunoResearch Labs) for 1 h at room temperature. After again rinsing in PBS, sections were mounted onto microscope glass slides and coverslipped using 90% glycerol in 0.1 M phosphate buffer, pH 7.4. To control for specificity of antibody staining, selected sections were submitted to the same protocol but without including the primary antibodies.
Immunofluorescence was not observed in control sections.
Confocal microscopy
Slices labeled with FITC were examined and scanned in a Radiance 2000 (Bio-Rad, Hertfordshire, UK) confocal microscope attached to a Nikon Eclipse E800 fluorescence microscope. The laser was an argon/krypton mixed gas laser with exciting wavelengths for FITC (488 nm). LaserSharp software (Bio-Rad) was used to establish optimal conditions for collecting images. The optimal conditions for confocal imaging of IDUA immunoreactivity were the following: the lens was a Â 20 objective (Nikon; Plan Apo Â 20/0.75); laser power was 10%; gain was 34.7; offset was 0.0; optical sections were scanned at a regular increment of 1 mm; the zoom factor was from 1 to 10; scan speed was 500 lines/s; each optical section was scanned three times and Kalman filtering was then employed to reduce noise; the size of the image was 512 Â 512 pixels or 246 Â 246 mm and the pixel size was 0.48 Â 0.48 mm.
Quantification of a-L-iduronidase immunofluorescence
A single optical confocal image of the brain tissue stained with IDUA antibody was used to quantify OD of immunofluorescence using Scion Image Beta 4.0.2 program (Scion Corporation, Frederick, MD, USA). Optical density was measured in 15 randomly selected IDUA-positive cells (OD cell ) and in 15 adjacent background level cells (OD background ). The data were exported to Excel (Microsoft, Redmond, WA, USA), and results were expressed as mean7s.e.m.
Statistical analysis
For the dose response analysis (Figure 2) , we looked at the correlation between vector dose administered and the specific activity of IDUA in three different areas of 
